First Trimester Pre-Eclampsia Screening

First trimester pre-eclampsia screening is a comprehensive risk assessment performed between 11 and 14 weeks of pregnancy to evaluate the likelihood of developing pre-eclampsia later in pregnancy. Pre-eclampsia is a serious pregnancy complication characterised by high blood pressure and organ damage, typically occurring after 20 weeks of pregnancy.

The screening combines multiple factors to calculate an individualised risk score. These include maternal characteristics, medical history, blood pressure measurements, specialised blood tests measuring placental proteins (PAPP-A and PlGF), and Doppler ultrasound assessment of uterine artery blood flow. This multi-modal approach provides more accurate risk prediction than traditional methods relying solely on maternal history.

The screening identifies women with increased risk, allowing for preventive interventions such as low-dose aspirin therapy and enhanced monitoring throughout pregnancy. Early screening may help identify women at risk of developing pre-eclampsia, both in early pregnancy and at term, allowing timely monitoring and management.

Early pre-eclampsia screening can support pregnancy management. Identifying high-risk women in the first trimester may allow preventive measures, such as low-dose aspirin, which research suggests can help reduce pre-eclampsia risk when started before 16 weeks.

The screening enables personalised pregnancy care based on individual risk profiles. Women identified as high-risk receive enhanced monitoring, allowing earlier detection of developing complications. This proactive approach can help prevent severe maternal and fetal complications through timely intervention.

For low-risk women, screening provides reassurance and supports routine antenatal care decisions. The comprehensive assessment also identifies other pregnancy risks, contributing to overall pregnancy management planning.

The screening’s high detection rates, particularly for early-onset pre-eclampsia, make it a valuable tool in modern obstetric care. Combined with preventive strategies, this approach has shown potential to reduce intensive care admissions, preterm births, and perinatal mortality associated with pre-eclampsia.

First-trimester pre-eclampsia screening costs vary depending on the components included and the healthcare setting. The comprehensive assessment typically includes professional consultation fees, ultrasound scanning, blood tests, and risk calculation analysis.

Factors affecting overall cost include the complexity of ultrasound assessment, the number of biomarkers tested, and whether screening is combined with other first-trimester assessments. Some centres offer package pricing combining pre-eclampsia screening with routine first-trimester screening and nuchal translucency assessment.

While representing an additional pregnancy expense, many women find the screening valuable for pregnancy planning and peace of mind. The potential to prevent serious complications through early intervention may offset screening costs through reduced need for intensive monitoring or emergency care later in pregnancy.

Consultation with our Gynaecologist includes a discussion of screening costs and payment options. Some practices offer flexible payment arrangements to improve accessibility.

First-trimester pre-eclampsia screening offers expectant mothers valuable insight into their pregnancy risks. This comprehensive assessment enables personalised care strategies, potentially preventing serious complications through early intervention. While no screening test is perfect, the combination of maternal factors, biomarkers, and ultrasound assessment provides an accurate risk prediction currently available. Understanding your individual risk empowers informed decision-making and appropriate pregnancy management planning.